TRPV4 mediates IL‐1‐induced Ca2+ signaling, ERK activation and MMP expression

Abstract

AbstractCa2+ permeation through TRPV4 in fibroblasts is associated with pathological matrix degradation. In human gingival fibroblasts, IL‐1β binding to its signaling receptor (IL‐1R1) induces activation of extracellular regulated kinase (ERK) and MMP1 expression, processes that require Ca2+ flux across the plasma membrane. It is not known how IL‐1R1, which does not conduct Ca2+, generates Ca2+ signals in response to IL‐1. We examined whether TRPV4 mediates the Ca2+ fluxes required for ERK signaling in IL‐1 stimulated gingival fibroblasts. TRPV4 was immunostained in fibroblasts of human gingival connective tissue and in focal adhesions of cultured mouse gingival fibroblasts. Human gingival fibroblasts treated with IL‐1β showed no change of TRPV4 expression but there was increased MMP1 expression. In mouse, gingival fibroblasts expressing TRPV4, IL‐1 strongly increased [Ca2+]i. Pre‐incubation of cells with IL‐1 Receptor Antagonist blocked Ca2+ entry induced by IL‐1 or the TRPV4 agonist GSK101. Knockout of TRPV4 or expression of a non‐Ca2+‐conducting TRPV4 pore‐mutant or pre‐incubation with the TRPV4 inhibitor RN1734, blocked IL‐1‐induced Ca2+ transients and expression of the mouse interstitial collagenase, MMP13. Treatment of mouse gingival fibroblasts with GSK101 phenocopied Ca2+ and ERK responses induced by IL‐1; these responses were absent in TRPV4‐null cells or cells expressing a non‐conducting TRPV4 pore‐mutant. Immunostained IL‐1R1 localized with TRPV4 in adhesions within cell extensions. While TRPV4 immunoprecipitates analyzed by mass spectrometry showed no association with IL‐1R1, TRPV4 associated with Src‐related proteins and Src co‐immunoprecipitated with TRPV4. Src inhibition reduced IL‐1‐induced Ca2+ responses. The functional linkage of TRPV4 with IL‐1R1 expands its repertoire of innate immune signaling processes by mediating IL‐1‐driven Ca2+ responses that drive matrix remodeling in fibroblasts. Thus, inhibiting TRPV4 activity may provide a new pharmacological approach for blunting matrix degradation in inflammatory diseases.